Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ponezumab

A humanized monoclonal antibody (IgG2deltaA) raised against amyloid beta peptides with Alzheimer disease treatment application. Ponezumab recognizes… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular… 
2017
2017
The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti‐A… 
2017
2017
Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's… 
2016
2016
Prominent cerebral amyloid angiopathy is often observed in the brains of elderly individuals and is almost universally found in… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2014
Review
2014
Amyloid-beta (Aβ) is suggested to play a causal role in the pathogenesis of Alzheimer’s disease (AD). Immunotherapies are among… 
  • figure 1
Highly Cited
2013
Highly Cited
2013
ObjectivesPonezumab is a humanized antiamyloid beta (A&bgr;) monoclonal antibody designed to treat Alzheimer disease (AD… 
Highly Cited
2013
Highly Cited
2013
ObjectivePonezumab (PF-04360365) is a humanized anti–amyloid beta (A&bgr;) monoclonal antibody designed for treatment of… 
Highly Cited
2012
Highly Cited
2012
Alzheimer's disease, the most common cause of dementia in the elderly and characterized by the deposition and accumulation of… 
2012
2012
Ponezumab (PF-04360365) is a novel humanized IgG2Δa monoclonal antibody that binds to amyloid-β (Aβ). It is designed to have… 
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 4
2012
2012
Cerebral vasogenic edema and microhemorrhages are potential safety concerns for compounds intended to treat subjects with…